Status:
COMPLETED
Ghrelin Levels in Pancreatic Cancer Patients
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The primary outcome measure for this study is plasma ghrelin level.
Detailed Description
The primary outcome measure for this study is plasma ghrelin level, and the two primary comparison are: * Patients with cachexia versus patients without cachexia * Patients with cachexia versus healt...
Eligibility Criteria
Inclusion
- Histological or cytological proof of pancreatic adenocarcinoma
- The control are will include healthy age-matched patients without cancer
- The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss
- Patients must have recovered from any major infections and/or surgical procedures
Exclusion
- Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state
- Patients on appetite stimulant and those receiving total parenteral nutrition
- Patients who have undergone gastrectomy or those who have gastric ulcers
- Patients receiving active chemotherapy
- No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00225745
Start Date
April 1 2004
End Date
September 1 2015
Last Update
October 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756